This open-label, multicentre, multinational trial evaluated the efficacy and safety of telmisartan used alone or as addon therapy in 2121 adults with mild-tomoderate essential hypertension. Patients received telmisartan 40 -80 mg once daily for 12 weeks and could participate in the study for up to 96 weeks, or until a marketed supply of telmisartan became available. Mean change from baseline in mean seated trough diastolic blood pressure (DBP) after 12 weeks' treatment, the primary endpoint, was -11.8 mmHg in the intent-to-treat population. The corresponding mean change in mean seated trough systolic blood pressure (SBP) was -20.2 mmHg. Both changes were statistically significant. Mean DBP and SBP reductions were apparent from week 4 and maintained throughout the treatment period. Telmisartan was well tolerated; the most common adverse events were headache (6%) and dizziness (3%), and 10% of adverse events were considered drug-related. In conclusion, telmisartan is an effective and well-tolerated drug when used as monotherapy or add-on treatment in this broad population of patients.
Introduction
The fundamental purpose of blood pressure control among individuals with hypertension is to prevent and limit targetorgan damage, thereby reducing the incidence of cardiovascular disease and improving the clinical outcome. 1, 2 Over a decade ago, a landmark analysis of nine prospective observational studies, involving almost 420 000 individuals, established that there is a linear, positive and continuous relationship between the usual (clinic) levels of diastolic blood pressure (DBP) and the risk of stroke, myocardial infarction, end-stage renal disease and congestive heart failure. 3 The increase in risk can be attributed to structural and functional changes in the target organs. Within the range of DBP studied (approximately 70 -110 mmHg), there was no evidence for a threshold level below which the risk of stroke or coronary heart disease did not continue to fall. Thus, for the majority of people, lowering the blood pressure should reduce their cardiovascular risk.
The renin-angiotensin-aldosterone system (RAAS), through angiotensin II, contributes both to hypertension and to many of the pathological target-organ responses to elevated blood pressure. Angiotensin II mediates its activity via two main receptor subtypes: AT 1 and AT 2 . Virtually all of the known actions of angiotensin II in blood pressure regulation and osmoregulation are the consequence of AT 1 receptor stimulation. These effects include vasoconstriction, aldosterone and vasopressin release, renal tubular sodium reabsorption, decreased renal blood flow and sympathetic nervous system stimulation.
Activation of the AT 1 receptor is also considered an important step in cardiovascular pathology. It promotes the growth and proliferation of vascular smooth muscle cells, fibroblasts, coronary endothelial cells and cardiomyocytes. These effects may contribute to vascular media hypertrophy or neointima formation, left ventricular hypertrophy, congestive heart failure, post-infarct remodelling, nephrosclerosis and atherosclerosis. 4, 5 In contrast, AT 2 receptor stimulation appears to have largely protective effects, such as the control of cell proliferation, cell differentiation and development, angiogenesis, wound healing, tissue regeneration and apoptosisbiological processes that counteract the trophic AT 1 receptor-mediated responses. 6, 7 Identification of the pivotal role of the RAAS in the pathophysiology of hypertension prompted the development of antihypertensive agents that interfere specifically with this system. Among these drugs are the angiotensin-converting enzyme (ACE) inhibitors and, more recently, the angiotensin II receptor blockers (ARBs). Inhibition of ACE prevents the conversion of angiotensin I to angiotensin II, thereby reducing angiotensin II levels, but it also prevents the catabolism of other biologically active peptides such as bradykinin, substance P and prostaglandins. It is believed that accumulation of these peptides may induce the cough that is experienced by up to 20% of patients on ACE inhibitors. 8, 9 Angiotensin II receptor blockers target the final step of the RAAS axis, by preventing the binding of angiotensin II to AT 1 receptors. Specific AT 1 receptor blockade should inhibit all of the negative effects associated with angiotensin II, yet preserve any favourable effects mediated through unopposed AT 2 receptors. 10 -12 Furthermore, as a class the ARBs are extremely well tolerated, with sideeffect profiles similar to that of placebo; in particular, there is no increased incidence of cough compared with placebo. 13 Short-and long-term clinical trials have shown that telmisartan is an effective and well-tolerated ARB in patients with mild-tomoderate essential hypertension. 14 -20 Studies utilizing ambulatory blood pressure monitoring have shown that a single daily dose provides smooth and sustained 24-h blood pressure control. 21 -25 Telmisartan is well tolerated as monotherapy and also when combined with other anti-hypertensive medications, including the thiazide diuretic hydrochlorothiazide (HCTZ). 19,20,26 -29 The open-label, uncontrolled, multicentre, clinical-experience trial presented here sought to evaluate the efficacy and safety of telmisartan alone or as add-on therapy in subjects with essential hypertension over a treatment period of up to 96 weeks in 18 countries throughout the world. The results of this study would provide prescribers with valuable pre-launch experience of the drug.
Patients and methods

PATIENTS
The men and women enrolled in this study had mild-to-moderate essential hypertension that was newly diagnosed and either untreated or inadequately treated. Mild-tomoderate hypertension was defined as a mean seated DBP of 90 -114 mmHg and/or a mean seated systolic blood pressure (SBP) of 140 -200 mmHg, as measured by cuff sphygmomanometry. All participants were ≥ 18 years of age.
Exclusion criteria were severe renal or hepatic impairment (in the judgement of the investigator), uncorrected volume or sodium depletion (in the judgement of the investigator), primary aldosteronism, hereditary fructose intolerance, biliary obstructive disorders, or hypersensitivity to any component of telmisartan tablets (telmisartan, povidone, meglumine, sodium hydroxide, sorbitol and magnesium stearate). In addition, individuals who had participated in another clinical trial in the month prior to screening, those who had any medical condition that would prevent them from completing the trial safely, and women who were pregnant, breastfeeding or of childbearing potential but not using an adequate method of contraception were ineligible.
STUDY DESIGN
This was an open-label, uncontrolled clinical trial conducted at 194 centres in 18 countries (Argentina, Brazil, Canada, Croatia, Czech Republic, Estonia, Germany, Hungary, Latvia, Lithuania, Mexico, Nigeria, The Philippines, Poland, Russia, Slovakia, Slovenia and Turkey). The study protocol was reviewed and approved by the appropriate national, regional or investigational ethics committee or institutional review board for each centre. In addition, the study complied with good clinical practice, regulatory requirements and the Declaration of Helsinki, 1996. All subjects provided written informed consent prior to enrolment in the study.
The study design and clinic visit schedule is summarized in Fig. 1 . Patients were enrolled in the trial if they satisfied all the inclusion criteria and none of the exclusion criteria at an initial screening visit and at a baseline evaluation 4 weeks later (week 0).
Telmisartan 40 mg tablets were dispensed to eligible patients at the baseline visit, with instructions to take one tablet every morning at 09.00 (± 1 h) except on clinic visit days, when the medication was administered after the trough blood pressure had been measured.
Some patients initially received telmisartan 20 mg once daily, but a protocol amendment 10 months after the study commencement discontinued this practice. Patients on telmisartan 20 mg subsequently had their dose increased to 40 mg once daily, or were withdrawn from the study if they were unable to tolerate the higher dose.
From week 4 onwards, the telmisartan dose could be increased if, in the opinion of the investigator, there was an inadequate blood pressure response. The dose could be titrated to either 40 mg or 80 mg, depending on the starting dose for the patient. Patients with mild-to-moderate hepatic impairment did not receive a dose higher than 40 mg, since telmisartan clearance may be lower in such individuals. 30 In accordance with that country's dosing recommendations, patients recruited in Canada received telmisartan 80 mg once daily (unless there were specific reasons contraindicating this, such as hepatic impairment). The dose could be reduced to telmisartan 40 mg if 80 mg was not tolerated.
C Ingino, C Farsang, A Laucevicius et al.
Open-label study of telmisartan Week 0 Baseline (Visit 2)
Week 4 (Visit 3)
Week 8 (Visit 4)
Follow-up Discharge patient
Week 12 Primary timepoint (Visit 5)
Incorporate followup assessments in Visit 5
Incorporate followup assessments in Visit 6
Week 24 (Visit 6)
Incorporate followup assessments in Visit 7
Week 36 (Visit 7)
Incorporate followup assessments in Visit 8
Week 48 (Visit 8)
Incorporate followup assessments in Visit 9
Week 60 (Visit 9)
Incorporate followup assessments in Visit 10
Week 72 (Visit 10)
Incorporate followup assessments in Visit 11
Week 84 (Visit 11)
Incorporate followup assessments in Visit 12
Week 96 (Visit Patients returned to the clinic at intervals of 4 weeks until 12 weeks of treatment had been completed, when the primary endpoint was evaluated. They could then continue receiving telmisartan in the study until week 96 if deemed appropriate by the investigator and if the drug was not commercially available in their country. (Doctors were free to prescribe telmisartan once it was marketed in their country.) Such patients were assessed every 12 weeks to determine whether the drug should be withdrawn, they should be prescribed marketed telmisartan (if it had become available) or they should continue on telmisartan as part of the study. All other patients discontinued the study at week 12 and a final follow-up evaluation was not required. Patients leaving the study could still receive telmisartan if it was commercially available and thought to be of clinical benefit.
Patients were considered to have prematurely discontinued treatment if they stopped taking telmisartan more than 1 day prior to week 12, or stopped taking the drug at or after week 12 for any reason other than lack of efficacy. In addition, patients were withdrawn from the study for any of the following reasons: (i) A seated DBP or SBP exceeding 114 mmHg or 200 mmHg, respectively, at any clinic visit; (ii) An adverse event leading to drug withdrawal; (iii) Pregnancy; (iv) Non-compliance with the clinic visit schedule; (v) At the patient's request; (vi) At the discretion of the investigator (based on routine clinical practice and experience). Patients who completed the study and those who were withdrawn prematurely attended a follow-up visit 2 weeks later.
Patients were instructed to bring any unused medication to each clinic visit to allow compliance to be assessed. If compliance was outside the range 90 -110%, the investigator decided whether or not the patient should continue in the trial. Details of any concomitant medication were also recorded at each clinic visit. Investigators could add other anti-hypertensive agents, in particular hydrochlorothiazide (HCTZ), if further blood pressure reduction was required.
EFFICACY EVALUATIONS
Seated trough blood pressure (approximately 24 h post-dose) was determined at all clinic visits using a standard mercury sphygmomanometer. After a 5-min rest in a sitting position, three blood pressure measurements were taken at 2-min intervals. The mean of the three readings for SBP and DBP was used in the efficacy evaluations.
The primary efficacy endpoint was the change from baseline in the mean seated trough DBP after 12 weeks of telmisartan treatment. Secondary endpoints included the change from baseline in the mean seated trough SBP after 12 weeks of telmisartan treatment, changes from baseline in the mean seated trough SBP and DBP at other clinic visits (weeks 4, 8, 24, 36, 48, 60, 72, 84 and 96), the percentage of patients needing an increase in telmisartan dose during the first 12 weeks of treatment, and the percentage of patients continuing to take telmisartan after week 12. The last endpoint provides a measure of patients' satisfaction with the drug and wish to continue treatment. The percentage of patients responding to treatment was also assessed at week 12: a controlled patient was defined as one with an SBP < 140 mmHg and a DBP < 90 mmHg; a systolic response was defined as an SBP < 140 mmHg or a ≥ 10 mmHg reduction from baseline (for patients with an C Ingino, C Farsang, A Laucevicius et al.
Open-label study of telmisartan SBP ≥ 140 mmHg at baseline); and a diastolic response was defined as a DBP < 90 mmHg or a ≥ 10 mmHg reduction from baseline (for patients with a DBP ≥ 90 mmHg at baseline).
SAFETY EVALUATIONS
The extent of exposure to each telmisartan dose and to all doses was calculated. Details of all adverse events, including the incidence, intensity and relationship to telmisartan treatment, were monitored throughout the entire study period. Additional safety assessments included changes in heart rate and changes in laboratory parameters (clinical chemistry, haematology and urinalysis) judged clinically significant by the investigator.
STATISTICAL ANALYSES
This study was open-label with no comparator group and was not powered to detect specific changes, therefore a sample size estimate based on power calculations was not conducted. The safety population, which was used for demographic and safety assessments, comprised all patients who had received at least one dose of telmisartan. Efficacy analyses were performed on the intent-to-treat (ITT) population, which consisted of patients who had received at least one dose of telmisartan and who had undergone a baseline evaluation and at least one on-treatment seated trough blood pressure measurement. All statistical analyses were performed using SAS ® statistical software and were interpreted using the two-sided 5% level of significance. Changes from baseline in blood pressure were analysed using a paired Student's t-test. A P-value was derived from this test and 95% confidence intervals (CIs) for the absolute value and the change from baseline were calculated. Checks were conducted to verify that the differences between baseline and treatment end were approximately normally distributed and that the assumptions of the test were satisfied.
Patients who started on telmisartan 20 mg prior to the introduction of the amendment prohibiting this practice, were grouped with those who started on telmisartan 40 mg for all analyses except for extent of exposure.
Results
PATIENTS
The safety population comprised 2121 subjects who took at least one dose of telmisartan. Of these, 55 had no evaluable efficacy data at baseline or post-baseline and were thus excluded from the ITT population (n = 2066). A total of 257 of the 2121 (12.0%) patients discontinued the study prematurely. Reasons for discontinuation were adverse events (n = 79, 3.7%), lost to follow-up (n = 76, 3.6%), withdrawal of consent (n = 44, 2.1%), protocol violation (n = 20, 0.9%), SBP > 200 mmHg or DBP > 114 mmHg (n = 11, < 0.5%), or 'other' reasons (n = 27, 1.3%). Table 1 summarizes the patient demographic data and baseline characteristics for the safety population. Approximately half the subjects were women, three-quarters were white, and the mean age was 55.5 years. The most commonly used concomitant medications were aspirin (n = 385, 18.2%), HCTZ (n = 262, 12.4%) and atenolol (n = 187, 8.8%).
Most patients were started on telmisartan 40 mg (n = 1548, 73.0%). Only 5.9% (n = 125) started on telmisartan 20 mg, and 21.1% on telmisartan 80 mg (n = 448). If telmisartan became commercially available in that country from week 12 onwards, patients were withdrawn from the study and switched to the marketed drug if appropriate. As a result, the number of patients included in the analyses decreased steadily after week 12 to only 38 patients at week 96.
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Open-label study of telmisartan EFFICACY Efficacy analyses were conducted on the ITT population (n = 2066). The mean (± SD) seated trough DBP for these patients was 96.1 ± 7.7 mmHg at baseline, decreasing to 84.3 ± 8.9 mmHg after 12 weeks of telmisartan treatment. This mean change from baseline at week 12 (primary endpoint) of -11.8 mmHg (95% CI -12.2 to -11.4 mmHg, n = 1941) was both statistically significant (P < 0.001) and clinically relevant.
The mean (± SD) seated trough SBP decreased from a baseline value of 157.6 ± 13.5 mmHg to 137.3 ± 15.5 mmHg at week 12. This mean change from baseline at week 12 of -20.2 mmHg (95% CI -20.9 to -19.5 mmHg, n = 1941) was again statistically significant (P < 0.001) and clinically important. 
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The time courses of the reductions in SBP and DBP from baseline are shown in Fig. 2 . Blood pressure changes from baseline were apparent and statistically significant at week 4 (-14.5 ± 15.5 mmHg for SBP and -8.4 ± 9.1 mmHg for DBP, n = 2066, P < 0.001), and were maintained throughout the study until week 96 (-21.7 ± 16.4 mmHg for SBP and -14.1 ± 6.9 mmHg for DBP, n = 38). 
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The percentages of patients whose hypertension was controlled or who achieved a systolic response and/or a diastolic response at weeks 4, 8 and 12 are shown in Table 2 . The majority of patients who responded did so after 4 weeks of telmisartan treatment.
A total of 667 out of 1957 (34.1%) patients had their telmisartan dose increased by week 12. After week 12, 1620 out of 2066 (78.4%) patients continued to take telmisartan as part of the study.
A subgroup analysis that grouped together all centres within each country indicated that the anti-hypertensive effect of telmisartan was similar in all 18 participating countries. At week 12, the mean (± SD) change from baseline in the mean seated trough DBP ranged from -9.4 ± 8.4 mmHg in Brazil to -15.2 ± 7.5 mmHg in Germany, and the mean (± SD) change from baseline in the mean seated trough SBP ranged from -13.5 ± 14.1 mmHg in the Czech Republic to -25.3 ± 15.5 mmHg in Germany (Table 3 ).
COMPLIANCE
Overall, compliance with telmisartan treatment was good: the mean (± SD) compliance ranged from 98.6 ± 8.2% to 99.9 ± 3.1%.
SAFETY
The median exposure to any dose of telmisartan was 98 days. The median exposure to telmisartan 20 mg was 55 days, to telmisartan 40 mg was 77 days and to telmisartan 80 mg was 91 days, although many patients would have received more than one dose level. Overall, 76.2% of the patients (n = 1616) were exposed to telmisartan for more than 12 weeks.
Telmisartan was generally well tolerated. Of the 2121 patients in the safety population, 716 (33.8%) reported one or more adverse events over a treatment period of up to 96 weeks. Adverse events reported by ≥ 2% of patients are shown in Table 4 . A total of 222 (10.5%) of the patients on telmisartan experienced one or more adverse events considered by the investigator to be drugrelated. Headache (n = 52, 2.5%) was the most frequently reported drug-related adverse event.
During treatment, 29 (1.3%) patients developed non-fatal serious adverse events; the most common of these was hypertension (n = 4, < 0.2%). Four of the serious adverse events were judged to be possibly drugrelated (vertigo, skin rash and jaundice, myocardial infarction and hypotension). Controlled response: systolic blood pressure < 140 mmHg and diastolic blood pressure < 90 mmHg. Systolic response: systolic blood pressure < 140 mmHg or a ≥ 10 mmHg reduction from baseline (for patients with a systolic blood pressure ≥ 140 mmHg at baseline). Diastolic response: diastolic blood pressure < 90 mmHg or a ≥ 10 mmHg reduction from baseline (for patients with a diastolic blood pressure ≥ 90 mmHg at baseline). There was one death: an 81-year-old woman suffered a myocardial infarction 80 days after starting telmisartan therapy and 1 day after her last dose. This death was not considered to be treatment-related. A total of 79 (3.7%) patients withdrew from the study due to adverse events, mainly headache (n = 18, < 0.8%).
One woman reported at week 12 that she was pregnant. From the dates given, it was calculated that she was exposed to study medication for approximately 2 months prior to conception and for 3 weeks during the first trimester. She was withdrawn from the study as a result of the pregnancy and subsequently gave birth to a healthy male child after 40 weeks' gestation.
In the ITT population, the mean (± SD) heart rate was 74.4 ± 9.3 beats/min at baseline and 73.2 ± 8.8 beats/min at week 12, amounting to a change from baseline of -0.9 beats/min (95% CI -1.3 to -0.5 beats/min, n = 1921). The mean (± SD) heart rate at week 96 was 73.7 ± 7.1 beats/min, representing 
Discussion
This open-label, multicentre, multinational, clinical-experience trial demonstrates the efficacy and tolerability of telmisartan 40 -80 mg once daily as monotherapy or as add-on therapy in patients with mild-tomoderate essential hypertension. Over a 12-week treatment period, telmisartan produced statistically significant and clinically relevant reductions from baseline in the mean seated trough DBP (primary endpoint) and the mean seated trough SBP. As reported previously, significant SBP and DBP reductions were apparent after just 4 weeks of treatment. 15 All blood pressure measurements were made at trough (i.e. 24 h after the previous dose of telmisartan). The magnitude of the blood pressure reductions at the end of the dosing interval reflects the long duration of action of telmisartan. This can be attributed to its pharmacokinetic profile: it has a long half-life (approximately 24 h), 15 it binds tightly (but insurmountably) to the AT 1 receptor and is released slowly with a low drug-receptor dissociation constant, 31 and it is highly lipophilic, 32 allowing it to permeate readily the plasma membrane and bind to intracellular proteins. This reservoir of protein-bound drug is released gradually over time. Furthermore, because telmisartan has a high volume of distribution (500 l), 33 it will disperse readily into the tissue compartment, thereby increasing the size of the intracellular protein-bound reservoir. The long duration of action of telmisartan should help to blunt the sharp rise in blood pressure that occurs post-awakening, which might, in turn, protect against the heightened early morning risk of cardiovascular events. 34 By week 12, over half of the patients had their blood pressure controlled, with higher proportions achieving either a systolic or a diastolic response. This is of clinical importance because the criteria for blood pressure control applied in this study conform to the target levels specified in international guidelines to minimize endorgan damage in a general population of hypertensive patients (i.e. SBP < 140 mmHg and DBP < 90 mmHg). 35, 36 Thus telmisartan should be of benefit to the majority of patients with mild-to-moderate hypertension. 
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The changes from baseline in blood pressure at week 12 were similar among the 18 countries participating in the study. Since these included countries in North America, South America, Africa, Europe and Asia, it would appear that telmisartan is a useful anti-hypertensive agent, either alone or as add-on therapy, across a range of ethnic groups. Telmisartan monotherapy, in common with other ARBs and ACE inhibitors (i.e. drugs that act on the RAAS), is generally more effective at lowering blood pressure in white than in black individuals. Even so, black patients still experience clinically meaningful SBP and DBP reductions with telmisartan, either alone or as combination therapy; 14,15 a combination of telmisartan plus HCTZ is particularly effective in black patients. 27 In the current study, clinically relevant changes from baseline in the mean seated trough SBP and DBP were observed at week 12 across all countries, regardless of the race of the subjects.
The present study also confirms the longterm tolerability of telmisartan in a general population of patients with mild-tomoderate essential hypertension. The good tolerability (plus the once-daily dosing schedule) is reflected in the excellent compliance with therapy, which is often a major challenge to achieving adequate blood pressure control. 37 -39 Most adverse events were not serious and were unrelated to treatment, and few led to patient withdrawal. Headache, dizziness and malaise/fatigue were the most frequent adverse events, and cough was reported by only 2% of patients. This pattern of adverse events is consistent with the patient population under study, and does not differ from that observed in patients receiving placebo in placebo-controlled studies with telmisartan. 14, 15, 23 Although one patient died during the study, this was not considered to be treatment-related.
There are obvious limitations to an openlabel, clinical-experience trial in hypertension. Blood pressure tends to fall irrespective of the intervention because of regression to the mean, and the placebo response can be fairly pronounced in patients with newly diagnosed or previously untreated hypertension. In this study a considerable proportion of the study population (43.9%) had long-standing hypertension (> 5 years since first diagnosis, but inadequately or not treated), and the consistent anti-hypertensive effect of telmisartan over the 96-week study period suggests that the blood pressure reductions were attributable primarily to medication and not to other factors.
In conclusion, this open-label, multinational study has confirmed that telmisartan, either as monotherapy or as add-on treatment, is an effective and welltolerated drug in a broad population of patients with mild-to-moderate hypertension. It produced statistically significant and clinically relevant reductions in the mean seated trough DBP and SBP after 12 weeks that were maintained until the end of the study at 96 weeks.
